The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
Abstract
Recently, we have described the biological correlations associated with the main translocations involving the 14q32 chromosomal region, that is, t(14q32), in patients with multiple myeloma (MM). We have now extended the analysis to the prognostic value of these chromosomal rearrangements in 168 consecutive patients with newly diagnosed MM receiving intensive chemotherapy within clinical trials of the Intergroupe Francophone du Myelome (IFM). Patients with t(4;14) displayed a poor outcome (short event-free survival and short overall survival), whereas those with t(11;14) displayed long survival. On the other hand, patients with neither t(4;14) nor t(11;14) presented an intermediate outcome. Importantly, chromosome 13 abnormalities (C13As) significantly influence the prognosis of this latter group. In contrast, C13As affected the outcome of the other patients to a much lesser extent, either because of an almost constant association (in the t(4;14) group) or because of a lack of any significant prognostic impact (in the t(11;14) group; only one event occurred in the 10 patients with t(11;14) and C13As). Considering that t(4;14) and t(11;14) (1) are the only (so far recognized) true, recurrent t(14q32)'s, (2) are linked to specific immunoglobulin isotypes, and (3) display specific outcomes, they represent distinct entities corresponding to a specific oncogenesis and prognosis. These data emphasized the interest in analyzing these two translocations by fluorescence in situ hybridization in prospective therapeutic trials in order to consider these translocations as distinct entities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Hypodiploidy is a major prognostic factor in multiple myeloma
Smadja, N. V., Bastard, C., Brigaudeau, C., Leroux, D., & Fruchart, C. (2001) · Blood · doi:10.1182/blood.v98.7.2229 · Cited by 390
Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.-J., Harousseau, J.-L., Minvielle, S., & Bataille, R. (2002) · Blood · doi:10.1182/blood.v99.6.2185 · Cited by 358
Self-citationCytogenetic findings in 200 patients with multiple myeloma
Sawyer, J. R., Waldron, J. A., Jagannath, S., & Barlogie, B. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)00284-i · Cited by 343
Zojer, N., Königsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Krömer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., et al. (2000) · Blood · doi:10.1182/blood.v95.6.1925 · Cited by 321
Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N. C., Anaissie, E., Spoon, D., et al. (2000) · Blood · doi:10.1182/blood.v95.12.4008 · Cited by 320
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Self-citationShaughnessy, J., Gabrea, A., Qi, Y., Brents, L., Zhan, F., Tian, E., Sawyer, J., Barlogie, B., Bergsagel, P. L., & Kuehl, M. (2001) · Blood · doi:10.1182/blood.v98.1.217 · Cited by 223
Lai, J., Zandecki, M., Mary, J., Bernardi, F., Izydorczyk, V, Flactif, M., Morel, P., Jouet, J., Bauters, F., & Facon, T. (1995) · Blood · doi:10.1182/blood.v85.9.2490.bloodjournal8592490 · Cited by 216
Self-citationAvet‐Loiseau, H., Facon, T. T. F., Daviet, A., Godon, C., Rapp, M.-J., Harousseau, J., Grosbois, B., & Bataille, R. (1999) · PubMed · Cited by 194
Self-citation
Cited by
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
Self-citationGenetics and Cytogenetics of Multiple Myeloma
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2876 · Cited by 687
Self-citationClinical and biologic implications of recurrent genomic aberrations in myeloma
Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., Dewald, G. W., Van Ness, B., Van Wier, S. A., Henderson, K. J., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3017 · Cited by 660
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
Metadata
- Authors
- Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.-L., Bataille, R., & Avet-Loiseau, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-09-01
- Volume
- 100
- Issue
- 5
- Pages
- 1579-1583
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2084657347
- Cited by
- 317
- References
- 16
- FWCI
- 13.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. https://app.cochat.ai/papers/10.1182/blood-2002-03-0749
- The paper
- Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.-L., Bataille, R., & Avet-Loiseau, H. (2002). Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. https://doi.org/10.1182/blood-2002-03-0749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.